Tamoxifen methiodide

Drug Profile

Tamoxifen methiodide

Alternative Names: PRS 311.003; Tamoxifen methyl iodide; TMI

Latest Information Update: 04 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmos Corporation; Weizmann Institute of Science
  • Class Antineoplastics; Phenyl ethers; Small molecules; Stilbenes; Trimethyl ammonium compounds
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Nov 2002 No development reported - Preclinical for Cancer in Israel (unspecified route)
  • 26 Nov 2002 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 25 Feb 2000 Pharmos has been granted a new patent for permanently charged steroid hormone derivatives in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top